Retatrutide has generated a lot of attention for its weight-loss results. Before anyone treats it as a finished product, it is worth being clear-eyed about two things: it is investigational and not FDA-approved [3], and like other drugs in this class it has a side-effect profile that the trials describe in detail.
First, the status
Retatrutide is being studied in clinical trials and is not available as a prescribed treatment outside of those trials [3]. It is not a Bon Health product. This article is educational.
Gastrointestinal effects
In its phase 2 obesity trial, the most common side effects were gastrointestinal — nausea, diarrhea, vomiting, and constipation. They were generally mild to moderate and dose-dependent, meaning more frequent at higher doses [1]. This mirrors what is seen across the incretin drug class.
The skin-sensitivity signal
The phase 2 trial and later safety analyses also reported a cutaneous hyperesthesia signal — heightened skin sensitivity or unusual skin sensations — that was more frequent on retatrutide than placebo and appeared dose-related [1][2]. As reported, these events were non-severe and did not lead participants to stop the drug in the trial.
We are deliberately not quoting a specific percentage here: the exact incidence should be read directly from the trial's published data rather than from secondary summaries, several of which circulate unverified numbers. If you see a precise figure elsewhere, check it against the primary source.
What this means in practice
For now, retatrutide remains a research compound. The responsible takeaway is that its early data look promising on weight loss, its side-effect pattern is broadly familiar for the class plus a notable skin-sensitivity signal worth watching, and final safety conclusions await larger phase 3 trials.
An available, evidence-backed option
If you want a doctor-guided treatment you can start today, tirzepatide and semaglutide both have extensive phase 3 evidence. Bon Health offers compounded tirzepatide from $170/month and compounded semaglutide from $120/month, prescribed and dosed by a licensed physician. Read our tirzepatide-vs-retatrutide comparison for more.
This article is for general education and is not medical advice. It does not replace the judgment of a licensed clinician. Compounded medications are not FDA-approved. Always talk with your healthcare provider before starting, changing, or stopping any medication.